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Summary
 
The p16
 
INK4a
 
-Rb tumour suppressor pathway is required
for the initiation and maintenance of cellular senescence,
a state of permanent growth arrest that acts as a natural
barrier against cancer progression. Senescence can be
overcome if the pathway is not fully engaged, and this
may occur when p16
 
INK4a
 
 is inactivated. p16
 
INK4a
 
 is frequently
altered in human cancer and germline mutations affecting
p16
 
INK4a
 
 have been linked to melanoma susceptibility.
To characterize the functions of melanoma-associated
p16
 
INK4a
 
 mutations, in terms of promoting proliferative
arrest and initiating senescence, we utilized an inducible
expression system in a melanoma cell model. We show
that wild-type p16
 
INK4a
 
 promotes rapid cell cycle arrest
that leads to a senescence programme characterized by
the appearance of chromatin foci, activation of acidic β β β β
 
-
galactosidase activity, p53 independence and Rb dependence.
Accumulation of wild-type p16
 
INK4a
 
 also promoted cell
enlargement and extensive vacuolization independent of
Rb status. In contrast, the highly penetrant p16
 
INK4a
 
 variants,
R24P and A36P failed to arrest cell proliferation and did
not initiate senescence. We also show that overexpression
of CDK4, or its homologue CDK6, but not the downstream
kinase, CDK2, inhibited the ability of wild-type p16
 
INK4a
 
 to
promote cell cycle arrest and senescence. Our data pro-
vide the first evidence that p16
 
INK4a
 
 can initiate a CDK4/
6-dependent autonomous senescence programme that is
disabled by inherited melanoma-associated mutations.
Key words: CDK4; CDK6; melanoma; naevi; p16
 
INK4a
 
;
senescence.
 
Introduction
 
The 
 
INK4a/ARF
 
 locus, situated on chromosome band 9p21, is
one of the most frequently altered sequences in human cancer
and germline mutations affecting this locus have been linked
to melanoma incidence in approximately 39% of melanoma-
prone families (Goldstein 
 
et
 
 
 
al
 
., 2006b). The lifetime risk of
melanoma in p16
 
INK4a
 
 germline mutation carriers ranges from
58% in Europe to 91% in Australia by the age of 80 (Bishop
 
et
 
 
 
al
 
., 2002). This locus encodes two potent, but distinct tumour
suppressor proteins; the cyclin-dependent kinase inhibitor,
p16
 
INK4a
 
 (Serrano 
 
et
 
 
 
al
 
., 1993) and the p53 activator p14ARF
(Quelle 
 
et
 
 
 
al
 
., 1995). Both proteins are critically important in the
regulation of cell cycle progression and senescence (reviewed
in Sharpless, 2005; Collado 
 
et
 
 
 
al
 
., 2007). p14ARF blocks prolif-
eration by inhibiting the p53 ubiquitin ligase hdm2, to stabilize
and activate p53 (Pomerantz 
 
et
 
 
 
al
 
., 1998; Stott 
 
et
 
 
 
al
 
., 1998;
Zhang 
 
et
 
 
 
al
 
., 1998) and ARF-null mouse embryonic fibroblasts
do not senesce (Kamijo 
 
et
 
 
 
al
 
., 1997). p16
 
INK4a
 
 promotes cell cycle
arrest by inhibiting the kinase activities of the cyclin D-dependent
kinases, CDK4 and CDK6, to maintain the retinoblastoma
protein, Rb in its hypophosphorylated, antiproliferative state
(Serrano 
 
et
 
 
 
al
 
., 1993). The progressive accumulation of p16
 
INK4a
 
is associated with the onset of replicative senescence in primary
human epithelial cells (Alcorta 
 
et
 
 
 
al
 
., 1996; Brenner 
 
et
 
 
 
al
 
., 1998)
and ectopic p16
 
INK4a
 
 expression induces growth arrest that
phenotypically resembles cellular senescence in human diploid
fibroblasts (Zhu 
 
et
 
 
 
al
 
., 1998; McConnell 
 
et
 
 
 
al
 
., 1999) and in
 
INK4a/ARF
 
-deficient murine melanocytes (Sviderskaya 
 
et
 
 
 
al
 
.,
2002). Furthermore, p16
 
INK4a
 
-deficient human diploid fibroblasts
and melanocytes, isolated from melanoma-prone individuals
with inactivating mutations affecting both 
 
INK4a
 
 alleles,
undergo delayed senescence (Sviderskaya 
 
et
 
 
 
al
 
., 2003; Brookes
 
et
 
 
 
al
 
., 2004; Jones 
 
et
 
 
 
al
 
., 2007) and are readily immortalized
by the introduction of the telomerase reverse transcriptase
(Sviderskaya 
 
et
 
 
 
al
 
., 2003).
Cellular senescence can be triggered by multiple mechanisms
including induction of the 
 
INK4a/ARF
 
 locus, telomere attrition,
DNA damage, oxidative damage and the aberrant proliferative
signals of oncogenes (reviewed in Collado & Serrano, 2006).
Once established, senescence permanently limits cellular prolif-
eration and protects against the development of malignant
cancer. Accordingly, senescent cells are abundant in premalignant
lesions of the skin, the lung and the pancreas whereas they are
almost completely absent in malignant tumours (Collado 
 
et
 
 
 
al
 
.,
2005). Senescent cells have been identified, both 
 
in vitro
 
 and
 
in vivo
 
, using a series of markers (reviewed in Collado & Serrano,
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2006; Campisi & d’Adda di Fagagna, 2007). Increased activity
of acidic 
 
β
 
-galactosidase, termed senescence-associated 
 
β
 
-
galactosidase (SA-
 
β
 
-gal) is the most widely accepted marker of
senescence cells (Dimri 
 
et
 
 
 
al
 
., 1995). More recently, the appear-
ance of DAPI-stained heterochromatic regions, known as
senescence-associated heterochromatic foci, which result in the
stable repression of some E2F target genes are involved in the
irreversible growth arrest associated with senescence (Narita
 
et
 
 
 
al
 
., 2003). These foci are enriched for histone H3 modified
at lysine 9 as well as its binding partner heterochromatin
protein-1
 
γ
 
 (HP-1
 
γ
 
) (Narita 
 
et
 
 
 
al
 
., 2003). Several other markers of
senescence have also been described and validated, including
the CDK inhibitor p15
 
INK4b
 
, an anti-apoptotic bcl-2 member,
Mcl-1 and the transcription factor, Dec1. Morphological
changes such as cell enlargement, vacuolization and cell flat-
tening are also typical of senescent cells (Collado 
 
et
 
 
 
al
 
., 2005).
Although the role of p16
 
INK4a
 
 in initiating senescence is well
documented (Vogt 
 
et
 
 
 
al
 
., 1998; McConnell 
 
et
 
 
 
al
 
., 1999; Dai &
Enders, 2000; Sviderskaya 
 
et
 
 
 
al
 
., 2002), there is a paucity of data
on the mechanisms underlying p16
 
INK4a
 
-induced senescence.
Moreover, little is known regarding the ability of melanoma-
associated p16
 
INK4a
 
 germline mutations to initiate and maintain
cellular senescence. This is particularly important as individuals
carrying p16
 
INK4a
 
 mutations have increased susceptibility to
melanoma, and usually display larger, more numerous and
dysplastic naevi (Gruis 
 
et
 
 
 
al
 
., 1995; Bennett & Medrano, 2002).
There is persuasive evidence that melanocytic naevi are growth-
arrested, senescent lesions, and it is likely that p16
 
INK4a
 
, which
is widely expressed in naevi, contributes to establishing cellular
senescence (Michaloglou 
 
et
 
 
 
al
 
., 2005; Gray-Schopfer 
 
et
 
 
 
al
 
.,
2006). This permanent growth arrest would be an efficient
barrier to melanoma development that may not be triggered
by melanoma-associated p16
 
INK4a
 
 variants.
To examine the autonomy and mechanism of p16
 
INK4a
 
-
induced senescence, we utilized a melanoma cell model with
inducible, physiological levels of p16
 
INK4a
 
 expression and com-
pared the impact of wild-type p16
 
INK4a
 
 expression to that of two
functionally distinct p16
 
INK4a
 
 melanoma-associated mutants.
The R24P mutation alters a highly conserved residue in the first
ankyrin repeat, is closely linked with familial melanoma in at
least 11 melanoma-prone kindreds (Della Torre 
 
et
 
 
 
al
 
., 2001;
Mantelli 
 
et
 
 
 
al
 
., 2002; Goldstein 
 
et
 
 
 
al
 
., 2006a) but behaved as
wild-type p16
 
INK4a
 
 in CDK6-binding assays (Harland 
 
et
 
 
 
al
 
., 1997;
Jones 
 
et
 
 
 
al
 
., 2007). This mutant was shown to be defective in
binding CDK4 (Harland et al., 1997) and inducing senescence
in human fibroblasts (Jones et al., 2007), but has not previously
been analysed in cells of melanocytic lineage. The A36P variant
identified in an Australian family (Holland et al., 1999) is
impaired in promoting cell cycle arrest (Becker et al., 2001), but
there is currently no data on its interaction with CDK4 and CDK6
in vivo. We show that wild-type p16
INK4a induced a rapid
proliferative arrest that was associated with cell enlargement,
vacuolization and appearance of heterochromatic foci. This
senescence programme was not triggered by stress to the
endoplasmic reticulum or DNA damage and was not activated
by the mis-sense melanoma-associated mutants, R24P and
A36P. Transient expression of CDK4 or CDK6, but not the
downstream kinase CDK2 overcame p16
INK4a-induced senes-
cence programme, and although Rb was critical to p16
INK4a-
mediated arrest, it was not required for p16
INK4a-induced cell
enlargement and vacuolization. This work confirms p16
INK4a-
driven senescence is intimately linked to CDK4/6-inhibition and
cell cycle arrest, and indicates that the melanoma-associated
mis-sense p16
INK4a mutants are unable to initiate an effective
CDK4/6-dependent senescence programme.
Results
Impact of induced wild-type p16
INK4a expression
To evaluate the influence of wild-type p16
INK4a accumulation on
cell proliferation and senescence, the WMM1175 melanoma cell
line, which is INK4a/ARF- and p53-null (Rizos et al., 1999) was engi-
neered to express wild-type p16
INK4a. In this WMM1175_p16
INK4a
cell line, p16
INK4a expression was induced with 4 mM isopropyl
β-D-1-thiogalactopyranoside (IPTG). Accumulation of p16
INK4a
was detected in the WMM1175_p16
INK4a cells 24 h post-induction,
and this was maintained for the 5 days of continuous IPTG
exposure (Fig. 1A). The level of p16
INK4a accumulation in the
WMM1175_p16
INK4a clone was comparable to p16
INK4a expres-
sion in normal, actively proliferating human epidermal melano-
cytes at passage 10 (Fig. 1B). The accumulation of p16
INK4a led
to the decreased levels of phosphorylated Rb (p-Rb
Ser807/811), the
loss of total Rb protein expression (Fang et al., 1998), and a slight
increase in the accumulation of CDK4 and CDK6. The p53-target
p21
Waf1 was not detectable and the endoplasmic reticulum-stress
response, which is required for  H-RAS-induced  senescence
(Denoyelle et al., 2006) was not activated by p16
INK4a, as determined
by the lack of induction of the endoplasmic reticulum-stress sensor
Grp78 (BiP) (reviewed in Gething, 1999) (Fig. 1A). Furthermore,
the DNA damage checkpoint, which mediates oncogene-
induced senescence (Bartkova et al., 2006; Di  Micco et al.,
2006), was not induced by p16
INK4a induction as there was no
evidence of increased DNA damage foci in p16
INK4a-expressing
cells, as marked by H2AX phosphorylation (data not shown).
As previously demonstrated (Becker et al., 2001), accumula-
tion of p16
INK4a potently inhibited the proliferation of the
WMM1175 cell line (Fig. 1C), and this was associated with a
rapid arrest in the G1-phase of the cell cycle with a concomitant
S-phase inhibition that was maintained over the 5-day induction
period (Fig. 1D). To ensure that IPTG alone did not affect cell
proliferation, the parental WMM1175_D2 cell line, which
expresses the lac repressor but not p16
INK4a, was treated as the
WMM1175_p16
INK4a clones and no changes were observed in
proliferation (data not shown) or cell cycle distribution (Fig. 1D).
To further examine the p16
INK4a-induced arrest, we analysed
two key markers of senescence: cell size and vacuolization.
Whereas IPTG treatment did not alter the phenotype of the
parental WMM1175_D2 cells (Fig.  1E), it caused an obvious
increase in the size and granularity, a marker of vacuolization,p16
INK4a-induced cellular senescence, S. Haferkamp et al.
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in the WMM1175_p16
INK4a cells (Fig.  1E). These p16
INK4a-
induced morphological changes were confirmed using micros-
copy. As shown in Fig. 2A, at 3 days post-induction the cells
induced for p16
INK4a expression had adopted characteristics of
senescent cells, appearing enlarged and flattened. These cells
were negative for the proliferation marker Ki67 and acquired
SA-β-gal activity (77 ± 3% of p16
INK4a-induced cells stained pos-
itive for SA-β-gal at 5 days post-induction). These senescence
features occurred as late markers of p16
INK4a function, and
appeared 2 days later than p16
INK4a-induced cell cycle arrest,
which was evident within 24  h post p16
INK4a induction (see
Fig. 1D). The uninduced WMM1175_p16
INK4a cells (Fig. 2A) and
IPTG-treated parental WMM1175_D2 cells (data not shown) did
not display a senescence phenotype and the majority of these
cells stained positive for Ki67.
To further investigate the response of the WMM1175
melanoma cells to p16
INK4a we analysed senescence-associated
heterochromatic foci by immunostaining with DAPI and HP-1γ.
Fig. 1 Induced expression of p16
INK4a inhibits Rb 
phosphorylation, limits cell proliferation and alters 
cell morphology. (A) Expression of the indicated 
proteins was determined by Western blot at 1, 3 
and 5 days after treatment of WMM1175_p16
INK4a 
cells with 4 mM IPTG. (B) Accumulation of p16
INK4a 
in IPTG-treated (5 days) WMM1175_p16
INK4a cells 
compared with levels of endogenous p16
INK4a in 
normal, actively proliferating human neonatal 
epidermal melanocytes (HEM 1259). (C) The 
impact of induced p16
INK4a expression on the 
proliferation of the WMM1175_p16
INK4a cells was 
determined over a 5-day induction period using the 
MTS assay. The results shown are expressed as the 
average ± standard deviation of at least two 
independent experiments performed in triplicate. 
(D) The percentage of cells in S-phase after 
induction of p16
INK4a for up to 5 days was 
determined by flow cytometry. S-phase inhibition 
was calculated from at least two independent 
induction experiments. Percentage S-phase 
inhibition in the IPTG-treated parental 
WMM1175_D2 cells, which expresses the lac 
repressor, but not the p16
INK4a transgene, is also 
shown. (E) The impact of IPTG-exposure on the size 
(Forward scatter) and granularity (Side scatter) of 
the WMM1175_p16
INK4a melanoma cells and the 
parental WMM1175_D2 cell line was investigated 
using flow cytometry on unfixed cells. These results 
are representative of at least two independent 
experiments.p16
INK4a-induced cellular senescence, S. Haferkamp et al.
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We observed a dramatic increase in the appearance of nuclear
foci at 3 and 5 days post-IPTG treatment; 49 ± 5% and 75 ± 5%
of p16
INK4a-induced cells stained positive for nuclear foci at 3
and 5 days post-induction, respectively, with the appearance of
large, prominent, often irregular shaped nuclei (Fig. 2A). The
accumulation the HP-1γ, within these nuclear foci confirmed
that they are senescence-associated heterochromatic foci
(Fig.  2B). Taken together our results confirm that wild-type
p16
INK4a can induce senescence in WMM1175 melanoma cells
in a p53- and p21
Waf1-independent manner.
Impact of melanoma-associated p16
INK4a mutations on 
melanoma cell senescence
Although it has been shown that wild-type p16
INK4a can pro-
mote an autonomous senescence programme (Dai & Enders,
2000), there has been no detailed analysis on the impact of
melanoma-associated mutations on this programme. This is
particularly relevant as there are significant variations in the
penetrance of p16
INK4a mutations for melanoma (Berwick et al.,
2006) and this may relate to loss of specific functions, including
the induction of senescence. We analysed two well-defined and
common p16
INK4a mutants that segregate with disease in high-
risk melanoma families. These mutant proteins were also
selected because they displayed expression levels comparable
to the wild-type p16
INK4a protein in the inducible WMM1175
melanoma cell model (Fig. 3A).
All clones expressing mutant p16
INK4a proteins were analysed
as the wild-type WMM1175_p16
INK4a clone in cell proliferation
and senescence assays. The R24P mutant, which retains CDK6
inhibitory activity, partially inhibited Rb phosphorylation and
slightly diminished the levels of total Rb over the 5-day induction
period (Fig. 3B). In contrast, the A36P mutant had no consistent
impact on Rb levels or its phosphorylation status (Fig.  3B).
Expression of the p16
INK4a mutations (R24P and A36P) had no
long-term inhibitory effect on WMM1175 cell proliferation
(Fig. 3C) and this correlated closely with the consistently weaker
inhibition of S-phase induced by the mutants when compared
with the sustained S-phase inhibition and G1 arrest observed
when the wild-type p16
INK4a protein was induced (Fig. 3D).
Furthermore, these mutant p16
INK4a proteins produced no
detectable changes in cell size and morphology (data not shown),
had no impact on heterochromatic foci and did not induce
SA-β-gal activity (Fig. 3E).
Fig. 2 Impact of induced p16
INK4a expression on the cellular senescence programme. (A) WMM1175_p16
INK4a cells were exposed to 4 mM IPTG over a 5-day 
period. The accumulation of p16
INK4a, cell proliferation (Ki67), chromatin condensation (DAPI) and the appearance of SA-β-gal was analysed. Cells enlarged to 
show DAPI-stained chromatin foci are indicated with arrows. Cell counts for each of these markers are shown as histograms, which correspond to the average 
± standard deviation of at least two independent induction experiments from a total of at least 500 cells. LM, light microscopy. (B) Representative examples 
of p16
INK4a-induced chromatin condensation (DAPI) and costaining for HP-1γ as surrogates for senescence-associated heterochromatin foci (indicated by arrows).p16
INK4a-induced cellular senescence, S. Haferkamp et al.
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p16
INK4a-induced arrest and senescence requires 
inhibition of CDK4 and CDK6
Given that the R24P variant, which binds and inhibits CDK6, but
not CDK4 (Jones et al., 2007), was still incapable of promoting
arrest, we hypothesized that inhibition of both CDK4 and CDK6
was required for p16
INK4a-induced arrest and senescence. After
screening a panel of human cancer cell lines for CDK4 and CDK6
expression (data not shown), the U20S cell line was selected,
as it accumulated approximately threefold higher levels of CDK6
compared to the WMM1175 cell line (Fig. 4A). U20S cells were
engineered to inducibly express the wild-type p16
INK4a or the
R24P mutant protein. As expected, expression of wild-type
p16
INK4a, but not R24P, arrested U20S cells and promoted their
senescence. p16
INK4a-induced senescence in the U20S cells was
associated with cell enlargement and SA-β-gal activity, but not
DNA heterochromatic foci (Fig. 4B).
Furthermore, when either CDK4 or CDK6 was ectopically
expressed in the WMM1175_p16
INK4a cell line, induced expres-
sion of p16
INK4a failed to inhibit cell proliferation and did not
induce senescence. In particular, in the presence of ectopic
CDK4 or CDK6 expression, p16
INK4a did not promote cell
enlargement, heterochromatic foci or SA-β-gal activity (Fig. 5).
In contrast, WMM1175_p16
INK4a cells transiently transfected
with vector only and induced for wild-type p16
INK4a expression
showed all the characteristic markers of senescence (Fig. 5).
To ensure that p16
INK4a-mediated cell cycle arrest was speci-
fically overcome by expression of its CDK4 and CDK6 binding
Fig. 3 Melanoma-associated p16
INK4a mutants fail to induce cell cycle arrest. (A) Expression of wild-type p16
INK4a, R24P and A36P mutant proteins in WMM1175 
melanoma cell clones was induced with 4 mM IPTG over a 5-day induction period and compared using immunoblotting. (B) Expression of p16
INK4a, total Rb, 
Ser
807/811-phosphorylated Rb and actin was determined 1, 3 and 5 days after treatment of WMM1175_R24P and WMM1175_A36P cells with 4 mM IPTG. 
(C) The impact of induced mutant p16
INK4a on the proliferation of the WMM1175_R24P and WMM1175_A36P cells was determined over the 5-day induction 
period using the MTS assay. The results shown are expressed as the average ± standard deviation of at least two independent experiments performed in triplicate. 
(D) The percentage of cells in S-phase after induction of p16
INK4a or a melanoma-associated p16
INK4a mutant in the WMM1175 cells was determined by flow 
cytometry. The percentage S-phase inhibition was calculated from at least two independent induction experiments. (E) Expression of the melanoma-associated 
variants R24P or A36P was induced in the WMM1175 melanoma cells and the impact on cell morphology (LM), proliferation (Ki67), chromatin condensation 
(DAPI) and SA-β-gal activity was analysed over a 5-day period. Representative examples of the 5-day IPTG induction point are shown. Cells enlarged to show 
DAPI-stained chromatin foci are indicated with arrows. Cell counts for the cell cycle markers are shown as histograms, which correspond to the average ± standard 
deviation of at least two independent induction experiments from a total of at least 500 cells. LM, light microscopy.p16
INK4a-induced cellular senescence, S. Haferkamp et al.
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partners, we also transiently introduced CDK2, a kinase that
accelerates and augments CDK4/6-initiated Rb hyperphospho-
rylation (reviewed in Johnson & Walker, 1999; Sherr, 1993).
Ectopically expressed CDK2 did not overcome the ability of
p16
INK4a to induce cell cycle arrest or senescence (Fig. 5). These
data confirm that the inhibition of both CDK4 and CDK6 kinase
activity is required for p16
INK4a-mediated cell cycle arrest and
senescence. More importantly, they suggest that all known
functions of p16
INK4a, including the induction of chromatin con-
densation and p16
INK4a-mediated changes in cell morphology
and size, depend on CDK4/6 binding and inhibition.
The Rb protein is the critical downstream target of 
p16
INK4a
It is well established that the downstream impact of p16
INK4a-
mediated inhibition of CDK4 and CDK6 activity is the hypo-
phosphorylation and activation of Rb, as shown in Fig. 1A. It
has also been recognized that p16
INK4a accumulation promotes
the rapid disappearance of Rb (Serrano et al., 1997; Fang et al.,
1998; Ausserlechner et al., 2005), and we observed Rb loss in
both the WMM1175 (Fig. 1A) and U20S cells (data not shown).
Considering that Rb loss coincided with cell cycle arrest and
occurred earlier than the onset of senescence (Rb loss and arrest
were detected 24  h post p16
INK4a induction, whereas senes-
cence was detected 72 h after p16
INK4a expression was induced;
see Figs 1A and 2A), it was important to establish whether Rb
depletion alone (with no p16
INK4a expression) promoted cell
cycle arrest and senescence. Silencing of Rb with an Rb-specific
silencing molecule, 72 h or 96 h post-transduction (Fig. 6A), did
not in itself promote cell cycle arrest or senescence as judged
by the continued proliferation of Rb shRNA-transduced
WMM1175 (data not shown) and WMM1175_p16
INK4a cells
(Fig. 6B). These Rb-null cells did not stain positive for SA-β-gal
activity, did not form DNA foci (Fig. 6B) and did not enlarge
(Fig. 6C). Thus, down-regulation of Rb expression alone does
Fig. 4 The melanoma-associated p16
INK4a R24P 
mutant fails to induce cell cycle arrest or 
senescence in U20S cells. (A) Expression of CDK4, 
CDK6 and actin was compared in the U20S and 
WMM1175 cells. Band intensities were determined 
by densitometric measurements using a 
phosphoimager (Molecular Dynamics). (B) Stable 
pools of U20S cells expressing inducible forms of 
wild-type p16
INK4a or R24P were exposed to 4 mM 
IPTG over a 5-day period. Representative examples 
of the 5-day IPTG induction time point are shown. 
The accumulation of p16
INK4a, cell proliferation 
(Ki67) and the appearance of SA-β-gal was 
analysed. Cell counts for these markers are shown 
as histograms, which correspond to the average 
± standard deviation of at least two independent 
induction experiments from a total of at least 500 
cells. LM, light microscopy.p16
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not inhibit cell cycle proliferation nor does it promote senes-
cence. More importantly, induced p16
INK4a could only promote
cell cycle arrest and cellular senescence, as judged by acquired
Ki67 staining and SA-β-gal activity and DNA foci formation, in
the presence of Rb (Fig. 6B).
Although loss of Rb did not initiate senescence and Rb was
required for p16
INK4a-mediated senescence it was important to
clarify whether Rb was the critical downstream target for all
p16
INK4a functions. This was particularly relevant as it has been
suggested that CDK4 and CDK6 may phosphorylate as yet
unidentified substrates (Ruas et al., 2007), and we have now
shown that these binding partners are critical for p16
INK4a-
induced senescence. Thus, the WMM1175_p16
INK4a cells were
transduced with a control shRNA or an Rb-specific silencing
molecule and 96 h post-transduction the cells were induced
for wild-type p16
INK4a expression. Analysis of these cells, 72 h
after p16
INK4a induction, revealed that Rb expression remained
effectively silenced and the cells remained inducible for
p16
INK4a expression (Fig.  7A). Intriguingly, the ability of
p16
INK4a to increase cell size and granularity did not require Rb,
and p16
INK4a induced these distinctive changes in cell morphology
regardless of Rb status (Fig. 7B).
Considering that depletion of Rb occurs after the onset of
p16
INK4a-induced arrest but prior to the onset of p16
INK4a-
induced senescence (see Fig. 1), it was possible that reinstating
the expression of Rb could influence p16
INK4a-induced senes-
cence. As shown in Fig. 7(C), however, when Rb expression was
transiently reintroduced into the WMM1175_p16
INK4a cells,
p16
INK4a retained its activity and effectively promoted cell cycle
arrest followed by senescence. Thus, p16
INK4a-induced cell cycle
arrest and senescence requires the complete inhibition of CDK4
and CDK6 activity and the transient activation of Rb. The sub-
sequent loss of Rb expression appears incidental to p16
INK4a-
mediated arrest and senescence, although we are investigating
the precise mechanism of Rb loss. Furthermore, the p16
INK4a-
driven inhibition of CDK4 and CDK6 promotes changes in cell
morphology independent of Rb, suggesting additional kinase
targets may contribute to the activity of p16
INK4a.
Discussion
p16
INK4a is a highly penetrant melanoma tumour suppressor that
regulates cell cycle progression by inhibiting the kinase activities
of cyclin D-associated CDK4 and CDK6 (Serrano et al., 1993).
Fig. 5 CDK4 and CDK6 inhibition is critical to p16
INK4a-induced senescence. WMM1175_p16
INK4a cells were transfected with CDK4-EGFP, CDK6-EYFP, 
CDK2-HA or vector DNA (only the pEGFPN1 vector control is shown here), as indicated. Approximately 6 h post-transfection, cells were treated with PBS (–) 
or induced for p16
INK4a expression with 4 mM IPTG (+). At 72 h post-induction, cells were stained for transgene expression (CDK/GFP), markers of senescence 
(SA-β-gal, DAPI) and proliferation (Ki67), as indicated. Cell counts for each of these markers are shown as histograms, which correspond to the average ± standard 
deviation of at least two independent induction experiments from a total of at least 300 cells.p16
INK4a-induced cellular senescence, S. Haferkamp et al.
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Fig. 6 Silencing Rb expression does not promote an arrest or senescence response. (A) WMM1175 melanoma cells were transduced with a control shRNA or 
an Rb-specific silencing molecule, as indicated. The efficiency of transduction was controlled with co-expression of copGFP and was consistently above 90%. 
At 72 h and 96 h post-transduction (PT), cells were harvested and protein expression analysed using SDS-PAGE with the indicated antibodies. (B) 
WMM1175_p16
INK4a cells were transduced with a control or a Rb-specific shRNA molecule and approximately 96 h post-transduction the cells were treated 
for 3 days with IPTG (+) or PBS (–) and stained for markers of transduction (copGFP), senescence (SA-β-gal, DAPI) and proliferation (Ki67), as indicated. Cell 
counts for each of these markers are shown as histograms, which correspond to the average ± standard deviation of at least two independent induction 
experiments from a total of at least 300 cells. (C) The impact of Rb silencing on the size (Forward scatter) and granularity (Side scatter) of the WMM1175 
melanoma cells was investigated, 96 h post-transduction, using flow cytometry on paraformaldehyde fixed cells. These results are representative of at least 
two independent experiments.p16
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Active binary cyclin D-CDK complexes initiate Rb phosphorylation
driving cells towards DNA replication in S-phase. Although the CDK
inhibitory functions of p16
INK4a are well described, the mechanisms
underlying p16
INK4a-mediated senescence are poorly understood
and the relative contribution of p16
INK4a-induced senescence to
its role as a tumour suppressor has not been addressed.
A few studies have examined the impact of p16
INK4a on the
senescence of human dermal fibroblasts and melanocytes
derived from rare melanoma-prone individuals carrying germline
mutations in both INK4a/ARF alleles. These p16
INK4a-deficient
cells were resistant to oncogenic RAS-induced senescence
(Huot et al., 2002; Jones et al., 2007) and had an extended, but
finite lifespan that terminated with senescence (Sviderskaya
et al., 2003; Brookes et al., 2004). Interpretation of these results
is complicated, however, by the possible contribution of defec-
tive p14ARF (Huot et al., 2002; Sviderskaya et al., 2003;
Brookes et al., 2004), which is known to confer a growth advan-
tage when silenced (Voorhoeve & Agami, 2003). Moreover,
there is considerable variability in the different cell strains with
regard to their lifespan (Brookes et al., 2004; Jones et al., 2007),
p16
INK4a expression (Beausejour et al., 2003), chromosomal
stability (Sviderskaya et al., 2003) and inducibility of p16
INK4a by
the RAS oncogene (Jones et al., 2007). To avoid some of these
confounding effects, silencing molecules have been applied to
deliberately and specifically ablate p16
INK4a. Nevertheless, the
data remain inconclusive; in most, but not all reports, p16
INK4a
deficiency modestly extended the replicative lifespan of cells but
did not impair senescence (Bond et al., 1999; Voorhoeve &
Agami, 2003; Denoyelle et al., 2006). p16
INK4a was also not
essential for H-RAS-induced melanocyte senescence (Denoyelle
et al., 2006), although it was required for RAS-induced fibro-
blast senescence (Bond et al., 1999; Huot et al., 2002).
Fig. 7 p16
INK4a-induced arrest and senescence requires the expression of Rb.WMM1175_p16
INK4a melanoma cells were transduced with a control shRNA or an 
Rb-specific silencing molecule, as indicated. The efficiency of trasduction was controlled with the co-expression of copGFP and was consistently above 90%. 
At 96 h post-transduction cells were treated with PBS (–) or 4 mM IPTG (+) and 72 h post-induction cells were analysed. (A) Cells were harvested and protein 
expression analysed using SDS-PAGE with the indicated antibodies. (B) The impact of 72 h of p16
INK4a induction on the size (Forward scatter) and granularity 
(Side scatter) of the WMM1175_p16
INK4a melanoma cells was investigated, 96 h post-transduction with a control or Rb-specific shRNA molecule, using flow 
cytometry on paraformaldehyde fixed cells. These results are representative of at least two independent experiments. (C) WMM1175_p16
INK4a cells were 
transiently transfected with an Rb or empty expression plasmid, and approximately 6 h post-transfection the cells were treated for three days with IPTG (+) or 
PBS (–) and stained for Rb, markers of senescence (SA-β-gal, DAPI) and proliferation (Ki67), as indicated. Cell counts for each of these markers are shown as 
histograms, which correspond to the average ± standard deviation of at least two independent induction experiments from a total of at least 300 cells.p16
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As an alternative strategy, we applied an inducible melanoma
cell model to thoroughly characterize the p16
INK4a senescence
pathway, with a particular emphasis on the analysis of well-
established markers of senescence. We then examined the
impact of two melanoma-associated mis-sense p16
INK4a muta-
tions on the senescence of this melanoma cell model. By
utilizing an inducible cell clone we eliminated cell-related
variations and manipulated the induction of p16
INK4a and
melanoma-associated p16
INK4a variants, to obtain near-physio-
logical expression levels. As expected, the wild-type p16
INK4a
protein promoted rapid cell cycle arrest that was associated at
later time points with the onset of senescence and the appear-
ance of classic senescence markers, including enlarged cells with
heterochromatic foci and SA-β-gal activity. As expected, these
markers proved useful in combination, as none are specific or
persistent in all senescence cells (Collado & Serrano, 2006). In
fact, U20S cells induced to express wild-type p16
INK4a acquired
SA-β-gal activity, showed a large increase in cellular size but
did not feature condensed chromatin. Although senescence-
associated heterochromatic foci are associated with the silencing
of E2F-1 genes (Narita et al., 2003), it is evident that they are
late markers of senescence, occur later than E2F-1 target
gene silencing (data not shown) and can be absent in highly
vacuolized and arrested cells (Denoyelle et al., 2006).
The mis-sense p16
INK4a variants, R24P and A36P, failed to
inhibit proliferation and to initiate senescence. The R24P muta-
tion was able to slightly reduce the hyperphopshorylation of Rb,
presumably because it retains CDK6 inhibitory activity but this
was not sufficient to maintain a G1 arrest. This is consistent with
data indicating that this is a highly penetrant melanoma-
susceptibility mutant that has been identified in at least eight
melanoma-prone families worldwide (Goldstein et al., 2006b).
Furthermore, it reinforces that CDK4, rather than CDK6 (Shen-
nan et al., 2000), is the critical kinase in melanoma. CDK4 germ-
line mutations have been identified in eight melanoma-prone
families worldwide (Zuo et al., 1996; Soufir et al., 1998; Molven
et al., 2005; Pjanova et al., 2007; Soufir et al., 2007) and these
disrupt the interaction between p16
INK4a and CDK4 (Zuo et al.,
1996). Mouse embryonic fibroblasts derived from CDK4
R24C/R24C
mice (CDK4
R24C is resistant to p16
INK4a inhibition) (Rane et al.,
2002) and human diploid fibroblasts overexpressing CDK4 have
an extended lifespan (Morris et al., 2002; Ramirez et al., 2003)
and carcinogen-treated mice carrying oncogenic CDK4 are
highly susceptible to melanoma development (Sotillo et al.,
2001). Our results demonstrate that ectopic expression of wild-
type CDK4 overcame p16
INK4a-induced arrest and senescence,
and it is not surprising that overexpression of its homologue,
CDK6, but not the downstream kinase CDK2, would abrogate
p16
INK4a activity. Thus, the ability of p16
INK4a to bind and inhibit
CDK4 and CDK6 is directly linked not only to cell cycle regula-
tion but also to initiating the senescence programme.
The critical downstream target of the p16
INK4a-CDK4/6 com-
plex is Rb, which is strictly required for p16
INK4a-mediated cell
cycle arrest. Moreover, we now show that Rb is central to the
p16
INK4a-induced senescence programme, and that in the
absence of Rb p16
INK4a does not promote SA-β-gal activity or
chromatin condensation. Surprisingly, the status of Rb did not
affect the ability of p16
INK4a to induce large increases in cellular
size and extensive vacuolization, reminiscent of the morpho-
logical changes induced by various oncogenes (Denoyelle et al.,
2006). The mechanism and impact of this p16
INK4a activity
remains to be defined, although it is dependent on CDK4/6 inhi-
bition and is presumably associated with the ability of p16
INK4a to
elevate protein synthesis and ATP levels (Ausserlechner et al., 2005).
Although p16
INK4a-induced cellular senescence provides an
important brake to human cell transformation in culture its
contribution to the tumour suppressor functions of p16
INK4a
has been poorly defined. Our data confirm that senescence
induction is tightly linked to the cell cycle inhibitory actions of
p16
INK4a, and importantly that both these functions are disabled
by highly penetrant melanoma-associated variants. Further-
more, our data identify CDK4 and CDK6 as the central kinase
targets of p16
INK4a in the regulation of senescence. Our results
provide the first evidence that p16
INK4a can initiate an auto-
nomous senescence programme that is disabled by inherited
melanoma-associated mutations. This is consistent with the
notion that the senescence programme limits the development
of tumours and the inability to initiate and maintain senescence
is an important contributor to melanoma development.
Experimental procedures
Cell culture and transfections
Human WMM1175 melanoma cells (ARF-null, p53-null, Rb
+/+;
Rizos et al., 1999) and HEK293T cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM, Gibco BRL, Carlsbad, CA,
USA) supplemented with 10% foetal bovine serum and
glutamine. Human epidermal melanocytes (HEM1259) were
obtained from Cell Applications (San  Diego, CA, USA) and
grown in HAM’s F10 media, supplemented with ITS premix
(Becton Dickinson, Franklin Lakes, NJ, USA), TPA, IBMX, cholera
toxin, 20% foetal bovine serum and glutamine (modified from
Halaban et al., 1986). All cells were cultured in a 37 °C incu-
bator with 5% CO2.
The WMM1175_p16
INK4a cell clones carrying the stably inte-
grated p16
INK4a (wild-type or mutant) gene under IPTG-inducible
expression control has been described previously (Becker et al.,
2001). The U20S_p16
INK4a cell clones were generated as pre-
viously described (Becker et al., 2001), except that a pooled
population of transfected cells was analysed. p16
INK4a inducible
cells were maintained in DMEM/10% foetal bovine serum sup-
plemented with 250  μg mL
–1 hygromycin and 500  μg mL
–1
geneticin (Gibco). Stable cells were seeded 24 h prior to induction
in the absence of antibiotics and were induced with 4 mM IPTG.
For CDK2, CDK4, CDK6 and Rb transfections, cells (1 × 10
5)
were seeded on coverslips in six-well plates and transfected with
2 μg CDK4-pEGFPN1, CDK6-EYFPN1, CDK2-HA, Rb, pEGFPN1
(Clontech, Mountain View, CA, USA) or pCMV-HA vector using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).p16
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Lentivirus transductions
Lentiviruses were produced in HEK293T cells using the pSIH1-
H1-copGFP (Copepod green fluorescent protein) shRNA expres-
sion vector (Systems Biosciences, Mountain View, CA, USA)
encased in viral capsid encoded by three packaging plasmids
as described previously (Dull et al., 1998). Viruses were concen-
trated as described previously (Reiser, 2000). Viral titres were
determined using 1  × 10
5 U2OS cells/well in six-well plates,
transduced with serial dilutions of the concentrated viral stocks
in the presence of Polybrene (8 μg mL
–1; Sigma, St. Louis, MO,
USA). Cells were harvested 48 h post-transduction, analysed by
flow cytometry for GFP expression and viral titre calculated.
For Rb silencing experiments, cells were transduced at an MOI
of 10 with either a virus encoding Rb shRNA or a control shRNA,
with no homology to any human gene. Cells were incubated
for 72–96 h prior to analysis to allow expression of shRNA con-
structs and efficient silence of Rb.
Constructs
CDK6-EYFP was constructed by subcloning the CDK6 insert from
CDK6-PVL1292 (a gift from B. Sarcevic) into pEYFPC1 (Clontech).
The Rb-directed shRNA sequence corresponds to nucleotides
662–680 (GenBank accession number NM_000321.1). The
control shRNA sequence 5′-TTAGAGGCGAGCAAGACTA-3′
showed no homology to any known human transcript.
Western blotting
Total cellular proteins were extracted at 4 °C using RIPA lysis
buffer containing protease inhibitors (Roche, Basel, Switzerland).
Proteins (30–50 μg) were resolved on 12% sodium dodecyl
sulfate–polyacrylamide gels and transferred to Immobilon-P
membranes (Millipore, Bedford, MA, USA). Western blots were
probed with antibodies against p16
INK4a (N20, Santa Cruz Bio-
technology, Santa Cruz, CA, USA), p21
Waf1 (C-19, Santa Cruz),
Grp 78 (H129, Santa Cruz), total Rb (aa 332-344, Becton
Dickinson), phosphorylated p-Rb
Ser807/811 (#9308, Cell Signalling,
Danvers, MA, USA), α-tubulin (236-10501, Invitrogen),  β-actin
(AC-74, Sigma-Aldrich), CDK4 (DCS-31, Sigma-Aldrich) and
CDK6 (K6.90+K6.83, Neomarkers, Fremont, CA, USA).
Proliferation assays
Cells were seeded at 1000 cells per well in a 96-well plate, with
or without 4 mM IPTG. Number of viable cells was determined
daily over 5-day induction period using the MTS assay (Promega,
Madison, WI, USA) and analysed with the VICTOR
2 1420 Multi-
label Counter (PerkinElmer, Waltham, MA, USA).
Flow cytometry
For cell cycle analysis, cells were fixed in 70% ethanol at 4 °C
for at least 1 h, washed in PBS and stained with propidium
iodide (50 ng μL
–1) containing ribonuclease A (50 ng μL
–1). DNA
content from at least 6000 cells was analysed using ModFIT soft-
ware (Verity Software House, Topsham, ME, USA). The percent-
age of S-phase inhibition was calculated using the following
formula: [(percentage of S-phase cells in uninduced cells) – (per-
centage of S-phase cells in induced cells)/(percentage of S-phase
cells in uninduced cells)] × 100. Cell size and granularity was
determined using flow cytometry on unfixed cells or cells fixed
in 1% paraformaldehyde/PBS and analysed with CellQuest Pro
(BD Biosciences)
Indirect immunofluorescence
Cultured cells (3–4 × 10
4) seeded on coverslips in 12-well plates
were washed in PBS and fixed in 2% formaldehyde, 0.2% glu-
taraldehyde, 7.4 mM Na2HPO4, 1.47 mM KH2PO4, 137 mM NaCl,
and 2.68 mM KCl. Cells were then rinsed three times with PBS
and SA-β-gal activity was detected as previously described
(Dimri et al., 1995). The same cells were immunostained for 50
min with primary antibodies followed by a 50-min exposure to
Alexa Fluor 488- or Alexa Fluor 594-conjugated secondary IgG
(Molecular Probes, Carlsbard, CA, USA). Nuclear DNA was stained
with 1 μg mL
–1 DAPI for 10–15 min.
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